Spectroscopy specialist Starna Scientific has appointed Nathan Hulme as a director to help guide the company’s expansion plans.
Hulme’s main responsibilities will include assisting in setting out a business strategy for the company that will address communications with customers and dealers as well as involving leadership of the sales team.
A graduate from Merton College, Oxford University, Hulme has a degree in Philosophy, Politics & Economics (PPE), specialising in Finance and International Economics.
He has also completed a mini-MBA at Tanaka Business School, Imperial College that featured finance, strategy and marketing components.
Starna Scientific appoints Nathan Hulme as a director
To help guide expansion plans at the spectroscopy specialist
You may also like
Analysis
![Cochrane review links pharma payments to prescribing practices]()
Cochrane review links pharma payments to prescribing practices
A Cochrane review of 93 studies has linked pharmaceutical industry promotional activities with less appropriate prescribing and higher prescription costs, prompting renewed calls for stronger conflict-of-interest policies and greater transparency in the UK
Manufacturing
![Patented device reinvents Solid Phase Extraction]()
Patented device reinvents Solid Phase Extraction
Biotech Fluidics announce SPEedy - a device that provides an effortless way to perform Solid Phase Extraction (SPE) sample preparation procedures without need of an external vacuum and compatible with any adsorption chemistry or eluent composition
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
![Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)]()
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part II)
Standardised cell systems can reduce biological variability, but robust potency testing must also demonstrate accuracy, precision and linearity. ICH Q2(R2) provides the framework to establish this analytical confidence
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
![Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part I)]()
Standardising cell-based potency assays for biologics lot release: the case for cryopreserved ready-to-use cell systems (part I)
As biologics become increasingly complex, demonstrating consistent biological activity at lot release is essential. Yet the cell-based assays used to measure potency introduce significant challenges in standardisation, reproducibility and regulatory compliance
